Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 14.05.2018 7 Anticancer Res 1 BMC Cancer 1 Cancer 1 Cancer Cell 3 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 2 Carcinogenesis 1 Chest 1 Clin Cancer Res 1 Clin Nucl Med 1 Eur Respir J 2 Int J Oncol 1 Int J Radiat Oncol Biol Phys 6 J Cancer Res Clin Oncol 3 J Clin Oncol 1 J Thorac Cardiovasc Surg 8 J Thorac Oncol 14 Lung Cancer 2 Oncol Rep 1 Science

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Anticancer Res

1. LIAO TY, Liaw CC, Tsui KH, Juan YH, et al
   Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis.
   Anticancer Res. 2018;38:3187-3192.
   PubMed     Text format     Abstract available
   
   
2. KABURAGI T, Kiyoshima M, Nawa T, Ichimura H, et al
   Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
   Anticancer Res. 2018;38:3145-3150.
   PubMed     Text format     Abstract available
   
   
3. KAWAGUCHI Y, Okano T, Kakihana M, Kajiwara N, et al
   Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma.
   Anticancer Res. 2018;38:3127-3132.
   PubMed     Text format     Abstract available
   
   
4. TANAKA K, Toyokawa G, Tagawa T, Ijichi K, et al
   Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.
   Anticancer Res. 2018;38:3115-3118.
   PubMed     Text format     Abstract available
   
   
5. OHNO T, Kubouchi Y, Wakahara M, Nosaka K, et al
   Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma.
   Anticancer Res. 2018;38:3001-3007.
   PubMed     Text format     Abstract available
   
   
6. RZECHONEK A, Grzegrzolka J, Blasiak P, Ornat M, et al
   Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.
   Anticancer Res. 2018;38:1987-1991.
   PubMed     Text format     Abstract available
   
   
7. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
   Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
   Anticancer Res. 2018;38:1927-1935.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. EZZELDIN N, El-Lebedy D, Darwish A, El Bastawisy A, et al
   Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
   BMC Cancer. 2018;18:525.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

9. GOLDWASSER F, Vinant P, Aubry R, Rochigneux P, et al
   Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
   Cancer. 2018 May 9. doi: 10.1002/cncr.31536.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Cell

10. HELLMANN MD, Callahan MK, Awad MM, Calvo E, et al
    Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
    Cancer Cell. 2018 Apr 21. pii: S1535-6108(18)30172.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

11. MORCOS PN, Nueesch E, Jaminion F, Guerini E, et al
    Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 10. pii: 10.1007/s00280-018-3597.
    PubMed     Text format     Abstract available
    
    
12. IMAI H, Minemura H, Sugiyama T, Yamada Y, et al
    Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Cancer Chemother Pharmacol. 2018 May 8. pii: 10.1007/s00280-018-3596.
    PubMed     Text format     Abstract available
    
    
13. KOBA T, Minami S, Nishijima-Futami Y, Masuhiro K, et al
    Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3598.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

14. DOHERTY JA, Grieshober L, Houck JR, Barnett MJ, et al
    Telomere length and lung cancer mortality among heavy smokers.
    Cancer Epidemiol Biomarkers Prev. 2018 May 9. pii: 1055-9965.EPI-17-1183.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

15. HSU HY, Lin TY, Hu CH, Shu DTF, et al
    Fucoidan Upregulates TLR4/CHOP-Mediated Caspase-3 and PARP Activation to Enhance Cisplatin-Induced Cytotoxicity in Human Lung Cancer Cells.
    Cancer Lett. 2018 May 7. pii: S0304-3835(18)30325.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

16. DAI X, Zhang N, Cheng Y, Yang T, et al
    RNA-binding Protein Trinucleotide repeat-containing 6A Regulates the Formation of Circular RNA 0006916, with Important Functions in Lung Cancer Cells.
    Carcinogenesis. 2018 May 3. pii: 4991992. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
17. YUAN JM, Carmella SG, Wang R, Tan YT, et al
    Relationship of the Oxidative Damage Biomarker 8-epi-prostaglandin F2alpha to Risk of Lung Cancer Development in the Shanghai Cohort Study.
    Carcinogenesis. 2018 May 3. pii: 4991979. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Chest

18. JACKSON V, Al-Ameri M, Sartipy U
    Weekday and Survival After Pulmonary Resections for Lung Cancer: A Swedish Nationwide Cohort Study.
    Chest. 2018;153:1284-1286.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

19. BAUML J, Levy B
    Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-18-0969.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

20. DERLIN T, Hartung D, Hueper K
    68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Extra-adrenal Paraganglioma in a Case of Complete Carney Triad.
    Clin Nucl Med. 2017;42:e527-e528.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

21. SUN YQ, Brumpton BM, Bonilla C, Lewis SJ, et al
    Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study.
    Eur Respir J. 2018 May 10. pii: 13993003.00329-2018.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

22. SHEN M, Chen Y, Xu L, Zhu R, et al
    Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.
    Int J Oncol. 2018 May 4. doi: 10.3892/ijo.2018.4394.
    PubMed     Text format     Abstract available
    
    
23. LIU K, Chen H, You Q, Ye Q, et al
    miR145 inhibits human nonsmall-cell lung cancer growth by dual-targeting RIOK2 and NOB1.
    Int J Oncol. 2018 May 3. doi: 10.3892/ijo.2018.4393.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

24. YEGYA-RAMAN N, Kim S, Deek MP, Li D, et al
    Daily Image Guidance With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Mar 30. pii: S0360-3016(18)30557.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

25. UEDA T, Aokage K, Nishikawa H, Neri S, et al
    Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.
    J Cancer Res Clin Oncol. 2018;144:835-844.
    PubMed     Text format     Abstract available
    
    
26. NAKASONE S, Mimaki S, Ichikawa T, Aokage K, et al
    Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2018;144:893-900.
    PubMed     Text format     Abstract available
    
    
27. BOYARSKIKH UA, Shadrina AS, Smetanina MA, Tsepilov YA, et al
    Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype.
    J Cancer Res Clin Oncol. 2018 May 8. pii: 10.1007/s00432-018-2658.
    PubMed     Text format     Abstract available
    
    
28. NGAM PI, Ling JZJ
    "Commentary on: Lung cancer screening with MRI: results of the first screening round"-Michael Meier-Schroers et al.
    J Cancer Res Clin Oncol. 2018 May 10. pii: 10.1007/s00432-018-2655.
    PubMed     Text format    
    
    
29. WANG K, Qu X, Liu S, Yang X, et al
    Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
    J Cancer Res Clin Oncol. 2018 May 4. pii: 10.1007/s00432-018-2653.
    PubMed     Text format     Abstract available
    
    
30. ZHANG L, Li J, Lv X, Guo T, et al
    MID1-PP2A complex functions as new insights in human lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2018;144:855-864.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

31. LEONARDI GC, Gainor JF, Altan M, Kravets S, et al
    Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    J Clin Oncol. 2018 May 10:JCO2017770305. doi: 10.1200/JCO.2017.77.0305.
    PubMed     Text format     Abstract available
    
    
32. LEE CK, Novello S, Ryden A, Mann H, et al
    Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.
    J Clin Oncol. 2018 May 7:JCO2017772293. doi: 10.1200/JCO.2017.77.2293.
    PubMed     Text format     Abstract available
    
    
33. RENGAN R, Redman M, Zeng J
    Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.
    J Clin Oncol. 2018 May 10:JCO2018783803. doi: 10.1200/JCO.2018.78.3803.
    PubMed     Text format    
    
    

    
    J Thorac Cardiovasc Surg

34. SWANSON SJ
    Good vibrations-better care for lung cancer patients.
    J Thorac Cardiovasc Surg. 2018 Apr 13. pii: S0022-5223(18)30994.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

35. CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
    Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
    PubMed     Text format     Abstract available
    
    
36. SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
    Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
    PubMed     Text format     Abstract available
    
    
37. NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
    Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
    PubMed     Text format     Abstract available
    
    
38. KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
    Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
    PubMed     Text format     Abstract available
    
    
39. GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
    Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
    PubMed     Text format     Abstract available
    
    
40. TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
    Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
    PubMed     Text format    
    
    
41. ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
    The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
    PubMed     Text format     Abstract available
    
    
42. VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
    The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer

43. TSAO MS, Yoon JY
    The eighth TNM classification for lung cancer-What is next?
    Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
    PubMed     Text format    
    
    
44. LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
    Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Lung Cancer. 2018;120:91-97.
    PubMed     Text format     Abstract available
    
    
45. ROBIN TP, Jones BL, Amini A, Koshy M, et al
    Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
    Lung Cancer. 2018;120:88-90.
    PubMed     Text format     Abstract available
    
    
46. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
    Lung Cancer. 2018;120:75-81.
    PubMed     Text format     Abstract available
    
    
47. RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
    Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
    Lung Cancer. 2018;120:62-69.
    PubMed     Text format     Abstract available
    
    
48. LEE CC, Zheng H, Soon YY, Foo LL, et al
    Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
    Lung Cancer. 2018;120:54-59.
    PubMed     Text format     Abstract available
    
    
49. KIMURA S, Harada T, Ijichi K, Tanaka K, et al
    Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
    Lung Cancer. 2018;120:98-107.
    PubMed     Text format     Abstract available
    
    
50. FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
    A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Lung Cancer. 2018;120:27-33.
    PubMed     Text format     Abstract available
    
    
51. BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
    Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Lung Cancer. 2018;120:142-148.
    PubMed     Text format     Abstract available
    
    
52. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Lung Cancer. 2018;120:137-141.
    PubMed     Text format     Abstract available
    
    
53. DU M, Thompson J, Fisher H, Zhang P, et al
    Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Lung Cancer. 2018;120:113-121.
    PubMed     Text format     Abstract available
    
    
54. GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
    PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Lung Cancer. 2018;120:108-112.
    PubMed     Text format     Abstract available
    
    
55. REITER MJ, Nemesure A, Madu E, Reagan L, et al
    Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
    Lung Cancer. 2018;120:1-6.
    PubMed     Text format     Abstract available
    
    
56. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
    Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
    PubMed     Text format    
    
    

    
    Oncol Rep

57. WANG M, Liu Y, Qian X, Wei N, et al
    Downregulation of occludin affects the proliferation, apoptosis and metastatic properties of human lung carcinoma.
    Oncol Rep. 2018 May 2. doi: 10.3892/or.2018.6408.
    PubMed     Text format     Abstract available
    
    
58. LIN C, Qin Y, Zhang H, Gao MY, et al
    EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in nonsmall cell lung cancer cells.
    Oncol Rep. 2018 May 8. doi: 10.3892/or.2018.6417.
    PubMed     Text format     Abstract available
    
    

    
    Science

59. NABHAN AN, Brownfield DG, Harbury PB, Krasnow MA, et al
    Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells.
    Science. 2018;359:1118-1123.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: